The Sabin Vaccine Institute Product Development Partnership (Sabin PDP) announced a new collaboration with Eisai Co., Ltd. to advance vaccine development efforts for neglected tropical diseases (NTDs). Sabin said that Eisai’s adjuvant material donation will enable the Sabin PDP to expand ongoing research and development for its leishmaniasis and Chagas disease vaccine candidates. This new partnership “represents an important first step in what will be an ongoing effort to find solutions to some of the world’s most pervasive diseases of poverty.”  The announcement noted that Eisai is among 13 pharmaceutical companies and other global partners, including WHO, the World Bank, the Bill & Melinda Gates Foundation and several national governments, to commit resources to controlling or eliminating 10 NTDs by 2020. The historic announcement, known as the London Declaration, marked the first time that the global health community joined together in a renewed effort to fight NTDs by offering in-kind support, expertise and funding. As part of their commitment, Eisai is providing their E6020 adjuvant material free of charge.

More at: http://www.sabin.org/news-resources/in-news/2012/09/12/eisai-and-sabin-vaccine-institute-partner-develop-vaccines-chagas-